STONEGATE SYSTEMSThe letter in one paragraph
On December 10, 2024, the FDA issued warning letter MARCS-CMS 695607 to Summit Research Peptides, a website selling GLP-1-class peptide compounds under a "for research use only" banner. The agency's finding: the products were unapproved new drugs and misbranded drugs under the FD&C Act, because the totality of the website - product pages, marketing language, customer-facing framing - established an intended use in humans. The research disclaimer on the same pages did not change that conclusion. The FDA said so explicitly. That single move is why this letter matters more than any peptide letter before it: it is the first clean, public, citable statement that a disclaimer cannot outvote the rest of your site.
If you run a research peptide store, this is the letter to actually read. Not a summary of it - the reasoning in it. Because everything the FDA has done to this industry since, including the 2026 batch of letters, runs on the logic Summit established.
What Summit sold: five GLP-1-class compounds under a research banner
Summit Research Peptides was not an edge case the FDA stretched to reach. The letter cited five products in the GLP-1 / metabolic class - the semaglutide- and tirzepatide-family compounds that were, by late 2024, the highest-visibility peptides in the country. These are active ingredients in FDA-approved drugs, which puts any online seller in the worst possible enforcement position: the agency does not have to argue about whether the compound is "drug-like." It already approved a drug containing it.
That product selection is the first lesson operators skip past. The FDA did not open its December 2024 enforcement push with an obscure research compound and a novel legal theory. It opened with compounds where the drug status was already settled and the only open question was intended use. Summit's defense to that question was the disclaimer. Which brings us to the part everyone quotes.
The ruling that matters: the disclaimer declared void
Summit's site did what nearly every peptide site does - it labeled products as for research use only, not for human consumption. The FDA's response, in the letter itself, was that these statements did not control. The agency looked at intended use the way it always has under the intended-use doctrine: from the totality of the evidence. Product names matching famous drugs. Descriptions written for a buyer, not a lab. Marketing that spoke to outcomes. A checkout flow built for consumers - single vials, card payment, ship to your house.
The FDA's position, plainly stated: a research-use disclaimer is a label. Intended use is determined by everything else. When the two conflict, everything else wins.
Understand what "void" means operationally. The FDA did not say Summit's disclaimer was missing, or badly worded, or in the wrong font size. It said the disclaimer was present and irrelevant, because the surrounding evidence of human intended use overwhelmed it. There is no wording fix for that. You cannot write a better sentence and win. The only fix is a site whose totality actually agrees with the sentence.
"Prevent, treat, or cure" - the exact language the FDA used
The statutory hook was the FD&C Act's drug definition: articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or function of the body. The letter walked Summit's own copy into that definition - the claims on product pages functioned as evidence that the products were intended to prevent, treat, or cure disease in humans. That made them unapproved new drugs (no approved application) and misbranded drugs (no adequate directions for use, which unapproved drugs can never have).
Two things to notice as an operator:
- Your own copy is the exhibit list. The FDA did not need lab tests, undercover buys, or customer interviews. It quoted the website. Every benefit claim, every outcome sentence, every drug-name comparison you publish is a line in a future letter.
- "Structure or function" is the wide net. You do not need to name a disease to trigger the drug definition. Copy that implies the compound does something to a human body is enough. This is why "it's just marketing" is the most expensive sentence in this industry.
The template it set: how the 2026 batch follows this letter
Summit was patient zero, not a one-off. The same day it went out, the FDA issued a companion letter to Prime Vitality - same structure, same totality reasoning, same disclaimer-does-not-control conclusion. Then the model scaled. On March 31, 2026, the agency published a batch of warning letters to seven peptide sellers at once, and if you lay them next to Summit the skeleton is identical: cite the compounds, quote the site's own copy as evidence of human intended use, acknowledge the RUO disclaimer, rule it void against the totality, conclude unapproved new drug plus misbranded.
The 2026 letters added refinements - the agency pierced internal code names to reach the underlying compounds, and it swept in sellers who thought careful product naming was cover - but the engine is Summit's. We break down the full batch in our index of FDA letters to peptide companies, and the sharpest single example of the matured template is the Gram Peptides letter from 2026. Read those after this one and you can watch a legal theory become an assembly line in fifteen months.
That is also why the downstream consequences arrive faster now. Payment processors and platforms read these letters too - a published warning letter is exactly the kind of evidence that gets a merchant account terminated and a store MATCH-listed. The FDA's timeline is slow; the processor's is not.
The companion letter: Prime Vitality, same day
The Prime Vitality letter matters because it kills the "they just didn't like Summit" reading. Two different companies, two different sites, one date, one identical analytical framework. When an agency ships the same reasoning twice on the same day, it is announcing a policy, not resolving a complaint. December 10, 2024 was the FDA telling the research peptide category, in duplicate: we have a repeatable test for you now, and the disclaimer is not part of the math.
Why a disclaimer is necessary but can never be sufficient
None of this means you should delete your RUO disclaimer. You need it - a site with no research-use framing at all is in a strictly worse position, and there are real requirements for doing it properly, which we cover in RUO disclaimer requirements. The point Summit settles is narrower and more brutal: the disclaimer is a claim about your site that the rest of your site either corroborates or destroys.
Think of it as testimony. A witness who says one thing while every document in the room says the opposite is not neutral - they are impeached. Summit's disclaimer was impeached by its own product pages. The FDA now runs that impeachment as a standard procedure, and it takes an investigator about as long as it takes to read your homepage.
So the honest operator question is not "is my disclaimer worded correctly?" It is "if a stranger read every page of my store with the disclaimer covered up, would they conclude this is a research supplier or a consumer pharmacy?" Most operators have never done that read. The FDA will. If you want it done for you first, the free 60-second audit performs exactly that read - every copy surface on your domain, scored against what the letters actually cite.
What a totality-proof store looks like instead
Since the disclaimer cannot carry the weight, the site has to. Concretely, a store that holds up under the Summit test looks like this:
- No GLP-1-class or approved-drug compounds. Full stop. Summit, Prime Vitality, and most of the 2026 batch were selling compounds that are active ingredients in approved or investigational drugs. That category is not a copywriting problem; it is a catalog problem. The compounds either come off the store or the store is a target.
- Zero benefit, outcome, or condition language anywhere. Product pages, category pages, emails, blog posts, meta descriptions, alt text. The letters quote all of it. On our builds this is enforced by a copy linter in the codebase - a human promising to "be careful" fails eventually; a linter that blocks the publish does not.
- A hard do-not-list at the product-creation layer, so a banned compound cannot be added to the catalog even by the owner at 11pm, and cannot be smuggled in under a rename or code name - the 2026 letters showed the FDA pierces those anyway.
- Researcher qualification and consent, logged. An age and qualified-researcher gate, plus a recorded consent on every order, gives your RUO position actual evidence behind it instead of a banner.
- No consumer-use accessories cross-sold next to compounds, no reviews describing personal results, no before/after imagery. Each one is a totality exhibit.
That is the whole thesis of compliance by construction: the FDA reads the totality of your site, so the totality is what you have to engineer - in code, where it cannot drift when you hire a copywriter or add a product in a hurry. A disclaimer is one sentence. The Summit letter is the FDA explaining, in a public document with a case number, that they will weigh it against every other sentence you have ever published.
This guide is general information for store operators, not legal advice. If you are responding to a warning letter, get a regulatory attorney - the response clock in these letters is 15 business days, and it is real.